Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Tax Deductibility Is Capital Issue At CHPA Conference In D.C.

This article was originally published in The Tan Sheet

Executive Summary

CHPA is planning a March 16 board meeting on Capitol Hill featuring several key members of Congress as a precursor to the trade group's annual meeting in Washington, D.C

You may also be interested in...



OTCs Would Be Tax Deductible Under House Bill; Supplement Status Unclear

A bill to make nonprescription drugs qualify as deductible medical expenses would make the law evenhanded to consumers using OTCs for chronic conditions, sponsor Rep. Jim DeMint (R-S.C.) says

IRS Rule On Flex-Spending Accounts A Boon For Chronic-Use OTCs, Switches

Schering-Plough's Claritin and Procter & Gamble's Prilosec OTC are likely to be major beneficiaries of an IRS ruling that nonprescription drugs can be covered by employee health flexible spending arrangements

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel